The application for marketing authorization of Subcutaneous Infliximab Biosimilar in China has been accepted.

On February 9th, Weikai and Bojian announced that the biologics license application for the subcutaneous formulation of the anti-amyloid beta antibody drug Luncaknemab has been accepted in January 2026, and the application has been granted priority review qualification by the China National Medical Products Administration. The global development and registration application of Luncaknemab is led by Weikai, while the product is commercialized and promoted jointly by Weikai and Bojian.